10x Genomics
TXG
76.10
-4.56
-5.65%
10x Genomics
US · TXG
#1311 by market cap
Listed 2019
76.10
-4.56
-5.65%
Live - 5344 symbols - heartbeat 96s ago
· 2026-10-08 06:44
Pre-market
73.50
-3.42%
After-hours
76.20
+0.13%
Overnight
75.78
-0.42%
- Market cap
- 9.92B
- P/E (TTM)i
- -128.98
- P/Bi
- 12.01
- EPSi
- -0.35
- Div yieldi
- 0.00%
- 52W posi
- 71%
Reader sentiment
Are you bullish or bearish on TXG?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 23.13, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +5.25% YoY
Margins
- Gross margin
- 69.05%
- Operating margin
- -17.25%
- Net margin
- -6.77%
Key ratios & quality
- Altman Z-Scorei
- 23.13
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 146.31M | 245.89M | 298.85M | 490.49M | 516.41M | 618.73M | 610.79M | 642.82M |
| Gross profit | 117.65M | 184.86M | 240.38M | 416.40M | 396.02M | 409.31M | 414.48M | 443.88M |
| Selling & admin expenses | 87.94M | 130.83M | 202.33M | 257.56M | 298.30M | 343.33M | 344.34M | 316.13M |
| Research & development | 47.54M | 83.10M | 123.38M | 211.75M | 265.67M | 270.33M | 264.70M | 238.63M |
| Operating profit | -17.82M | -29.07M | -85.32M | -52.91M | -167.94M | -204.35M | -194.56M | -110.89M |
| Pretax profit | -112.40M | -31.03M | -534.48M | -53.72M | -161.97M | -248.76M | -177.70M | -39.91M |
| Tax | 87.00K | 218.00K | 8.26M | 4.51M | 4.03M | 6.34M | 4.93M | 3.64M |
| Net profit | -112.49M | -31.25M | -542.73M | -58.22M | -166.00M | -255.10M | -182.63M | -43.54M |
| Basic EPS | -1 | -1 | -5 | -1 | -1 | -2 | -2 | 0 |
| Diluted EPS | -1.36 | -0.80 | -5.37 | -0.53 | -1.46 | -2.18 | -1.52 | -0.35 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 154.88M | 172.91M | 149.00M | 166.03M | 150.84M | 151.04M |
| Gross profit | 105.45M | 125.08M | 100.31M | 113.05M | 106.18M | 112.50M |
| Selling & admin expenses | 89.73M | 74.43M | 75.36M | 76.62M | 66.38M | 78.66M |
| Research & development | 64.25M | 61.22M | 57.19M | 55.97M | 56.85M | 56.79M |
| Operating profit | -48.53M | -10.57M | -32.24M | -19.54M | -17.05M | -22.96M |
| Pretax profit | -33.51M | 37.00M | -28.21M | -15.19M | -12.85M | -18.65M |
| Tax | 852.00K | 2.46M | -733.00K | 1.06M | 623.00K | -714.00K |
| Net profit | -34.36M | 34.54M | -27.47M | -16.25M | -13.47M | -17.93M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.28 | 0.28 | -0.22 | -0.13 | -0.10 | -0.14 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 106.24M | 480.84M | 774.37M | 747.59M | 635.04M | 596.02M | 584.39M | 684.45M |
| Cash & ST investments | 65.08M | 424.17M | 663.60M | 587.45M | 429.98M | 388.70M | 393.40M | 523.41M |
| Inventory | 8.57M | 15.27M | 29.96M | 59.97M | 81.63M | 73.71M | 83.11M | 56.34M |
| Total assets | 124.31M | 605.92M | 929.34M | 1.02B | 1.03B | 965.14M | 918.64M | 1.04B |
| Total current liabilities | 32.36M | 63.05M | 118.13M | 110.36M | 130.96M | 127.16M | 117.63M | 153.45M |
| Short-term debt | 4.19M | 9.88M | 5.94M | 5.13M | 9.04M | 11.52M | 9.29M | 10.99M |
| Long-term debt | 25.49M | 19.84M | -- | -- | -- | -- | -- | -- |
| Total liabilities | 344,297,000.00 | 185,840,000.00 | 190,269,000.00 | 201,258,000.00 | 223,237,000.00 | 224,100,000.00 | 208,502,000.00 | 245,039,000.00 |
| Total equity | -219.99M | 420.08M | 739.07M | 817.57M | 805.74M | 741.04M | 710.13M | 796.33M |
| Retained earnings | -231.12M | -262.37M | -805.10M | -863.32M | -1.03B | -1.28B | -1.47B | -1.51B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 579.73M | 655.66M | 659.83M | 684.45M | 669.73M | 674.67M |
| Cash & ST investments | 426.91M | 447.26M | 482.08M | 523.41M | 539.85M | 552.03M |
| Inventory | 74.71M | 68.97M | 61.96M | 56.34M | 53.49M | 52.62M |
| Total assets | 903.39M | 979.97M | 1.03B | 1.04B | 1.02B | 1.03B |
| Total current liabilities | 107.90M | 112.22M | 147.32M | 153.45M | 113.60M | 118.51M |
| Short-term debt | 9.44M | 9.67M | 10.54M | 10.99M | 11.33M | 12.02M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 196,498,000.00 | 206,691,000.00 | 242,241,000.00 | 245,039,000.00 | 201,435,000.00 | 204,520,000.00 |
| Total equity | 706.90M | 773.28M | 785.12M | 796.33M | 814.32M | 825.55M |
| Retained earnings | -1.50B | -1.47B | -1.49B | -1.51B | -1.52B | -1.54B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -76.41M | 34.63M | -217.90M | -21.37M | -33.61M | -15.20M | 6.66M | 136.05M |
| Depreciation & amortization | 3.91M | 7.07M | 19.02M | 28.25M | 33.01M | 43.62M | 43.71M | 43.82M |
| Free cash flow | -83.12M | -8.14M | -256.29M | -122.65M | -165.27M | -64.72M | -6.73M | 130.12M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 410.82M | 482.27M | 0 | -- | -- | -- | -- |
| Ending cash balance | 70.09M | 476.49M | 688.64M | 596.07M | 227.35M | 359.28M | 344.07M | 473.97M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 34.35M | 17.71M | 43.21M | 40.78M | 26.12M | 16.97M |
| Depreciation & amortization | 9.81M | 9.65M | 12.25M | 12.10M | 11.91M | 11.68M |
| Free cash flow | 32.46M | 16.13M | 42.53M | 39.00M | 24.52M | 15.39M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 377.06M | 397.71M | 432.71M | 473.97M | 490.29M | 502.51M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -31.24 | -93.64 | -7.48 | -20.45 | -32.98 | -25.17 | -5.78 |
| ROA %i | -112.53 | -8.56 | -70.70 | -5.98 | -16.21 | -25.59 | -19.39 | -4.44 |
| ROIC %i | -- | -23.93 | -86.69 | -6.79 | -18.95 | -30.81 | -24.10 | -6.99 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -37.16 | -35.95 | -18.37 |
| EBIT margin %i | -75.17 | -11.37 | -178.28 | -10.77 | -31.27 | -40.20 | -29.09 | -6.21 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | 20.24 |
| Current ratioi | 3.28 | 7.63 | 6.56 | 6.77 | 4.85 | 4.69 | 4.97 | 4.46 |
| Quick ratioi | 2.88 | 7.26 | 6.05 | 6.10 | 4.08 | 3.96 | 4.10 | 3.95 |
| Debt / assetsi | 23.87 | 4.90 | 6.78 | 8.05 | 9.25 | 9.88 | 8.99 | 8.10 |
| LT debt / equityi | -- | 4.72 | 7.72 | 9.40 | 10.69 | 11.32 | 10.33 | 9.21 |
| Interest coveragei | -45.66 | -9.08 | -316.76 | -61.03 | -339.28 | -7,537.27 | -44,424.00 | -- |
| Revenue CAGR (3Y) %i | -- | -- | 61.39 | 49.66 | 28.06 | 27.45 | 7.59 | 7.57 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -22.03 | -11.30 | -10.12 | -5.78 | -2.98 | -9.40 |
| ROA %i | -17.20 | -8.86 | -7.77 | -4.44 | -2.36 | -7.48 |
| ROIC %i | -21.27 | -11.62 | -10.60 | -6.99 | -4.22 | -10.01 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -24.56 | -12.31 | -21.77 | -6.21 | -1.32 | -12.14 |
| FCF / sales %i | 7.10 | 8.83 | 12.72 | 20.24 | 19.13 | 19.68 |
| Current ratioi | 5.37 | 5.84 | 4.48 | 4.46 | 5.90 | 5.69 |
| Quick ratioi | 4.44 | 5.05 | 3.93 | 3.95 | 5.25 | 5.09 |
| Debt / assetsi | 8.86 | 8.85 | 8.47 | 8.10 | 8.01 | 7.65 |
| LT debt / equityi | 9.99 | 9.97 | 9.74 | 9.21 | 8.60 | 8.09 |
| Interest coveragei | -51,133.33 | -15,864.40 | -- | -- | -- | 24,964.33 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Integrated research solutions, including instruments, consumables and related software for single100.00%
Quote time 2026-10-08 06:44:45 · For reference only, not investment advice and not tailored to your situation.